Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bitzer

Showing results (151-160 of 185) with videos related to

Pageof 19
Sort By:
Clinical Therapeutics|February 7, 2026
Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19Maddalena Marconato, Christopher Hackenbruch, Simon Jäger, et al.
Immunity|May 29, 2021
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumoniaStefanie Kreutmair, Susanne Unger, Nicolás Gonzalo Núñez, et al.
Nature Cancer|February 5, 2022
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancerRamona Rudalska, Jule Harbig, Marteinn T Snaebjornsson, et al.
The Journal of Allergy and Clinical Immunology|June 18, 2022
Preexisting comorbidities shape the immune response associated with severe COVID-19Stefanie Kreutmair, Manuel Kauffmann, Susanne Unger, et al.
Immunity|February 9, 2022
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumoniaStefanie Kreutmair, Susanne Unger, Nicolás Gonzalo Núñez, et al.
The Lancet. Gastroenterology & Hepatology|August 6, 2021
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
Nature Communications|October 27, 2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.
Journal of Hepatology|March 9, 2016
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyMichael Bitzer, Marius Horger, Edoardo G Giannini, et al.
Science Advances|September 1, 2023
BRAF<sup>Δβ3-αC</sup> in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggabilityManuel Lauinger, Daniel Christen, Rhena F U Klar, et al.
Neuro-Oncology Practice|May 13, 2024
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE)Lorenz Dörner, Lucia Grosse, Felix Stange, et al.
Pageof 19

Showing results (151-160 of 185) with videos related to

Sort By:
Pageof 19
Clinical Therapeutics|February 7, 2026
Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19Maddalena Marconato, Christopher Hackenbruch, Simon Jäger, et al.
Immunity|May 29, 2021
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumoniaStefanie Kreutmair, Susanne Unger, Nicolás Gonzalo Núñez, et al.
Nature Cancer|February 5, 2022
LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancerRamona Rudalska, Jule Harbig, Marteinn T Snaebjornsson, et al.
The Journal of Allergy and Clinical Immunology|June 18, 2022
Preexisting comorbidities shape the immune response associated with severe COVID-19Stefanie Kreutmair, Manuel Kauffmann, Susanne Unger, et al.
Immunity|February 9, 2022
Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumoniaStefanie Kreutmair, Susanne Unger, Nicolás Gonzalo Núñez, et al.
The Lancet. Gastroenterology & Hepatology|August 6, 2021
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
Nature Communications|October 27, 2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.
Journal of Hepatology|March 9, 2016
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyMichael Bitzer, Marius Horger, Edoardo G Giannini, et al.
Science Advances|September 1, 2023
BRAF<sup>Δβ3-αC</sup> in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggabilityManuel Lauinger, Daniel Christen, Rhena F U Klar, et al.
Neuro-Oncology Practice|May 13, 2024
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE)Lorenz Dörner, Lucia Grosse, Felix Stange, et al.
Pageof 19